Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An instance of thrombocytopenia that is inherited.
No HPO annotations are available for this condition.
Age of onset: at birth.
Individuals with ANKRD26-related thrombocytopenia usually present with lifelong mild-to-moderate thrombocytopenia with a normal platelet size and no syndromic associations. Incidental presentation following routine complete blood count is not uncommon. Some individuals are identified after developing a myeloid neoplasm such as acute myeloid leukemia or myelodysplastic syndrome. Bleeding history. Most individuals have normal hemostasis or a mild bleeding phenotype and do not develop severe spontaneous bleeding.
ANKRD26-related thrombocytopenia is a nonsyndromic congenital thrombocytopenia disorder lacking pathognomonic features and thus requiring molecular confirmation of a heterozygous ANKRD26 pathogenic variant to establish a diagnosis. Formal diagnostic criteria have not been published.
ANKRD26-related thrombocytopenia should be suspected in individuals with the following:
Source: GeneReviews — "ANKRD26-Related Thrombocytopenia"
No approved treatments are currently available for inherited thrombocytopenia. The disease remains an area of unmet medical need.
To establish the extent of disease and needs in an individual diagnosed with ANKRD26-related thrombocytopenia, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Surveillance for early detection of myeloid neoplasms is indicated in all individuals with ANKRD26-related thrombocytopenia. Guidelines have not been published on the type of testing or frequency of surveillance. A complete blood count on an annual basis with bone marrow examination if abnormalities are noted is commonly recommended.
Source: GeneReviews — "ANKRD26-Related Thrombocytopenia"
No clinical trials have been registered for inherited thrombocytopenia.
47 publications have been identified in PubMed for inherited thrombocytopenia. Research spans Basic Science / Preclinical (36%), Case Report / Case Series (19%), and Diagnostic / Biomarker (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 17 | 36% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 2:36 AM UTC
Complete blood counts
Source: GeneReviews — "ANKRD26-Related Thrombocytopenia"
Due to the clinical and genetic heterogeneity and low incidence of inherited platelet disorders, the diagnosis is challenging, and sometimes inherited platelet disorders are misdiagnosed as idiopathic thrombocytopenic purpura (immune thrombocytopenia; ITP). Complex diagnostic algorithms have been proposed . Table 2. Disorders to Consider in the Differential Diagnosis of ANKRD26-Related Thrombocytopenia
Disorder | Gene(s) | MOI | Clinical Features |
|---|---|---|---|
RUNX1 | AD | Nonsyndromic thrombocytopenia w/normal platelet size predisposition to myeloid neoplasms | FPD/AML:; Can have normal platelet counts; More bleeding due to platelet storage pool disorder (dense granule deficiency) ETV6-related thrombocytopenia (thrombocytopenia-5, ETV6-RT) |
ETV6 | AD | Nonsyndromic thrombocytopenia w/normal platelet size predisposition to myeloid neoplasms | ETV6-RT:; Can have red cell macrocytosis neutropenia; Predisposes to lymphoid malignancy CYCS-related thrombocytopenia (thrombocytopenia-4, CYCS-RT; OMIM 616216) |
CYCS | AD | Nonsyndromic thrombocytopenia w/normal platelet size | CYCS-RT: Does not predispose to neoplasms |
Immune thrombocytopenia (ITP) | NA | NA | Thrombocytopenia w/normal (or mildly elevated) platelet size, minimal bleeding unless thrombocytopenia is severe |
Source: GeneReviews — "ANKRD26-Related Thrombocytopenia"
Biomarker and diagnostic research for inherited thrombocytopenia has been reported in the published literature.
Consideration of bone marrow aspirate and biopsy at initial evaluation to exclude hematologic malignancies if there are other cytopenias, or abnormalities in:
Mean corpuscular volume
Cell morphology
Leukocyte differential
Consultation with a clinical geneticist and/or genetic counselor
Most individuals are asymptomatic and undergo observation and surveillance. When bleeding is present or a major surgical procedure is required, adjunct hemostatic agents such as antifibrinolytics or desmopressin can be given. Platelet transfusions are reserved for severe bleeding or procedures with a high bleeding risk . Thrombopoietin analogs have been used selectively for short periods of time (preoperative). The long-term safety has not been established .
Once a myeloid neoplasm has been diagnosed, careful consideration of stem cell transplant eligibility and pre-transplant therapies should be undertaken. This is best accomplished at a large academic institution with experience in the management of individuals with ger...
Source: GeneReviews — "ANKRD26-Related Thrombocytopenia"
If a myeloid neoplasm that requires allogeneic stem cell transplantation develops and a related donor is being considered, a donor who does not have the ANKRD26 pathogenic variant present in the family should be used .
Source: GeneReviews — "ANKRD26-Related Thrombocytopenia"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "ANKRD26-Related Thrombocytopenia"
View trials for inherited thrombocytopenia
9 |
19% |
Testing and diagnosis research | 7 | 15% |
Research summaries | 5 | 11% |
Disease patterns and progression | 5 | 11% |
New treatment approaches | 2 | 4% |
Other research | 1 | 2% |
Clinical study results | 1 | 2% |
Düzenli Kar Y (2026). [PMID: 41359897](https://pubmed.ncbi.nlm.nih.gov/41359897/). *Journal of pediatric hematology/oncology*. [Case Report / Case Series]
Al-Ansari RY (2026). [PMID: 41721658](https://pubmed.ncbi.nlm.nih.gov/41721658/). *Journal of investigative medicine high impact case reports*. [Case Report / Case Series]
Glembotsky AC (2026). [PMID: 42218063](https://pubmed.ncbi.nlm.nih.gov/42218063/). *Blood Rev*. [Review / Meta-Analysis]
Çiftçiler R (2026). [PMID: 41167018](https://pubmed.ncbi.nlm.nih.gov/41167018/). *Hematology, transfusion and cell therapy*. [Epidemiology / Natural History]
Ramsland AS (2026). [PMID: 41643484](https://pubmed.ncbi.nlm.nih.gov/41643484/). *Stem cell research*. [Basic Science / Preclinical]
Ding C (2026). [PMID: 42213791](https://pubmed.ncbi.nlm.nih.gov/42213791/). *PLoS Biol*. [Basic Science / Preclinical]
Schecter DR (2026). [PMID: 41635268](https://pubmed.ncbi.nlm.nih.gov/41635268/). *American journal of medical genetics. Part A*. [Diagnostic / Biomarker]
Glonnegger H (2026). [PMID: 42082146](https://pubmed.ncbi.nlm.nih.gov/42082146/). *Hamostaseologie*. [Diagnostic / Biomarker]
Muhammad E (2026). [PMID: 41676885](https://pubmed.ncbi.nlm.nih.gov/41676885/). *Platelets*. [Basic Science / Preclinical]
Xiangwen W (2026). [PMID: 41472573](https://pubmed.ncbi.nlm.nih.gov/41472573/). *Molecular genetics & genomic medicine*. [Case Report / Case Series]